Nebivolol Crescent Pharma (Nebivolol Hydrochloride)

Nebivolol, the active ingredient in Nebivolol Crescent Pharma, is a selective β1‑adrenergic antagonist presented as an oral tablet for oral use. It is used to lower elevated blood pressure in adults with hypertension.

GNH USA supplies Nebivolol Crescent Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebivolol is a beta‑blocker that acts on the cardiovascular system to control high blood pressure. - Essential hypertension: reduces systolic and diastolic pressure by decreasing heart rate and peripheral resistance. - Stage 1 hypertension: helps achieve target blood pressure when lifestyle measures are insufficient. - Stage 2 hypertension: provides additional blood‑pressure control in patients requiring more intensive therapy.

Nebivolol is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate discomfort. - Dizziness or light‑headedness, especially on standing. - Fatigue or general tiredness. - Nasal congestion or rhinorrhea. - Peripheral edema: mild swelling of ankles or feet. - Bradycardia: slower than normal heart rate.

Serious or Rare Side Effects: - Severe bradycardia or heart block requiring medical attention. - Acute bronchospasm in patients with reactive airway disease. - Hepatic dysfunction manifested by elevated liver enzymes. - Allergic reactions such as rash, pruritus, or angio‑edema. - Syncope or fainting episodes. - Cardiogenic shock in extreme cases.

Before initiating Nebivolol, clinicians should evaluate patient‑specific risk factors and monitor therapy. - Cardiovascular assessment: review heart rate, rhythm, and any history of heart block. - Renal impairment: adjust monitoring if creatinine clearance is reduced. - Hepatic disease: use caution in patients with liver dysfunction. - Concomitant beta‑blockers: avoid additive effects that may cause excessive bradycardia. - Pregnancy and lactation: prescribe only if benefits outweigh potential risks. - Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Nebivolol may interact with other medicines that affect heart rate, blood pressure, or drug metabolism.

Major Interactions (Avoid): - Other beta‑blockers: risk of profound bradycardia and hypotension. - Calcium‑channel blockers (verapamil, diltiazem): can increase plasma concentrations of nebivolol. - Strong CYP2D6 inhibitors (e.g., paroxetine, quinidine): may raise nebivolol levels.

Moderate Interactions (Monitor Closely): - Diuretics: may potentiate antihypertensive effect, requiring blood‑pressure checks. - ACE inhibitors or ARBs: combined therapy can enhance blood‑pressure lowering. - NSAIDs: may blunt antihypertensive response. - Antidiabetic agents: monitor glucose as beta‑blockade can mask hypoglycaemia signs.